On Tuesday, Jefferies initiated coverage on shares of Pyxis Oncology Inc. (NASDAQ:PYXS), assigning the stock a Buy rating with a new price target of $10.00. The firm highlighted the company's antibody-drug conjugate (ADC) platform as having significant growth potential. The lead candidate, '201, targets tumor stroma, which may lead to more effective treatments for high stroma burden tumors, such as pancreatic ductal adenocarcinoma (PDAC).
The analyst noted that the efficacy of Pyxis Oncology's '201 linker and payload is somewhat derisked by Pfizer (NYSE:PFE)'s positive efficacy signal with its own HER2 ADC. Furthermore, the safety profile of '201 has been promising, showing tolerability at higher doses compared to Pfizer's HER2 ADC. This safety aspect is particularly notable as it could play a critical role in patient treatment regimens.
The initial clinical data for '201 is expected in the fall of 2024 and could further derisk the program and the company's platform. The firm's positive outlook on Pyxis Oncology is reflected in the Buy rating, indicating confidence in the stock's future performance.
Jefferies' price target adjustment to $10.00 represents a significant endorsement of Pyxis Oncology's strategic direction and the potential of its ADC platform. The new target is set with the anticipation of upcoming clinical data that could reinforce the company's position in the oncology treatment landscape.
InvestingPro Insights
As Jefferies initiates coverage on Pyxis Oncology Inc. (NASDAQ:PYXS) with a Buy rating and a price target of $10.00, it's vital to consider the company's financial health and market performance. According to InvestingPro data, Pyxis Oncology holds a market cap of $253.76 million, yet it operates with a negative P/E ratio of -2.07, indicating that the company is not currently profitable. The negative adjusted P/E ratio for the last twelve months as of Q4 2023 stands at -3.44, reinforcing the company's earnings challenges.
InvestingPro Tips suggest that Pyxis Oncology has more cash than debt, which is a positive sign for financial stability, but it is also quickly burning through its cash reserves. This is a critical consideration for investors, as the company's ability to fund its operations and research is essential for its growth potential, especially in the high-risk biotechnology sector. Additionally, the company's gross profit margins are weak, and analysts do not expect Pyxis Oncology to be profitable this year. Despite a large price uptick over the last six months, with a 159.64% return, the stock has fared poorly over the last month, with a -21.06% return, indicating volatility that investors should be aware of.
For those interested in a deeper analysis, InvestingPro offers many more tips that can provide further insights into Pyxis Oncology's financials and performance. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.